Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Total Liabilities (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Total Liabilities for 7 consecutive years, with $86.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 33.02% to $86.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86.4 million through Dec 2025, up 33.02% year-over-year, with the annual reading at $86.4 million for FY2025, 33.02% up from the prior year.
  • Total Liabilities hit $86.4 million in Q4 2025 for IDEAYA Biosciences, down from $93.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $93.1 million in Q3 2025 to a low of $24.9 million in Q3 2023.
  • Historically, Total Liabilities has averaged $60.1 million across 5 years, with a median of $66.8 million in 2022.
  • Biggest five-year swings in Total Liabilities: skyrocketed 632.75% in 2021 and later crashed 62.22% in 2023.
  • Year by year, Total Liabilities stood at $79.8 million in 2021, then crashed by 51.76% to $38.5 million in 2022, then dropped by 26.71% to $28.2 million in 2023, then skyrocketed by 130.09% to $64.9 million in 2024, then soared by 33.02% to $86.4 million in 2025.
  • Business Quant data shows Total Liabilities for IDYA at $86.4 million in Q4 2025, $93.1 million in Q3 2025, and $81.6 million in Q2 2025.